-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palivizumab Biosimilar in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palivizumab Biosimilar in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palivizumab Biosimilar in Respiratory Syncytial Virus (RSV) Infections...
-
Product Insights
Post Menopausal Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Post Menopausal Osteoporosis - Drugs In Development, 2023’, provides an overview of the Post Menopausal Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post Menopausal Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Respiratory Syncytial Virus (RSV) Infections - Drugs In Development, 2023’, provides an overview of the Respiratory Syncytial Virus (RSV) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Respiratory Syncytial Virus (RSV) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab Biosimilar in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab Biosimilar in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab Biosimilar in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Denosumab Biosimilar in Post Menopausal Osteoporosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Denosumab Biosimilar in Post Menopausal Osteoporosis Drug Details: Denosumab biosimilar is under development for the...
-
Thematic Analysis
State of the Biopharmaceutical Industry in 2024 – Thematic Intelligence
Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you in: Examining the current attitudes of business leaders toward the emerging trends impacting the biopharmaceutical industry in the next 12 months. Benchmarking the impact of major themes on the biopharmaceutical industry in 2024, including emerging technologies, regulatory trends, macroeconomic trends, and industry trends. Identifying the most impactful anticipated regulatory approvals and drug launches in the industry in 2024, learning about top-selling drugs (2023 vs 2024), and obtaining...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NIM-1324 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NIM-1324 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NIM-1324 in Rheumatoid ArthritisDrug Details:NIM-1324 is under development for the treatment of rheumatoid...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – LABP-104 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LABP-104 in Rheumatoid Arthritis report and make more profitable business decisions. How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Xeruborbactam in Enterobacteriaceae Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Xeruborbactam in Enterobacteriaceae Infections Drug Details: Xeruborbactam is under development for the treatment of carbapenem-resistant...